{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-082092","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.145753+00:00","generated_at":"2026-05-31T22:58:48.696420+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcadia CEO Stanley Jacot resigns; CFO Schaefer promoted to CEO, Kawakami named CFO","bullets":["Stanley Jacot, Jr. resigned as president, CEO, and director on July 2, 2024; cash severance $288,077 + 12-month option acceleration + COBRA through Feb 2025.","CFO Thomas J. Schaefer appointed president and CEO effective July 5, 2024; he had been CFO since Jan 2023.","Mark Kawakami appointed CFO effective July 5, 2024; he was VP Finance since Jan 2023; base salary $212,063.","Separation Agreement includes general release of claims, confidentiality, and non-disparagement by Jacot."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-082092","json":"https://secwatch.observer/filing/0000950170-24-082092.json","markdown":"https://secwatch.observer/filing/0000950170-24-082092.md","text":"https://secwatch.observer/filing/0000950170-24-082092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/rkda-20240702.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:58:48.696420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a13e339e9","claim":"Stanley Jacot, Jr. resigned as president, chief executive officer and director at Arcadia Biosciences, Inc..","evidence_excerpt":"Mr. Jacot resigned as Arcadia’s president, chief executive officer and director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"president, chief executive officer and director"}],"fact_type":"executive_change"},{"claim_id":"74d85afc85","claim":"Mark Kawakami was appointed as chief financial officer at Arcadia Biosciences, Inc..","evidence_excerpt":"Arcadia’s board of directors appointed Mark Kawakami as Arcadia’s new chief financial officer to succeed Mr. Schaefer, effective as of July 5, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"chief financial officer"}],"fact_type":"executive_change"},{"claim_id":"bff8e7b513","claim":"Thomas J. Schaefer was appointed as president and chief executive officer at Arcadia Biosciences, Inc..","evidence_excerpt":"Arcadia’s board of directors appointed Thomas J. Schaefer, Arcadia’s current chief financial officer, to the position of president and chief executive officer of Arcadia, effective as of July 5, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"president and chief executive officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}